Catalytic mTOR inhibitors can overcome intrinsic and acquired resistance to allosteric mTOR inhibitors

We tested the antitumor efficacy of mTOR catalytic site inhibitor MLN0128 in models with intrinsic or acquired rapamycin-resistance. Cell lines that were intrinsically rapamycin-resistant as well as those that were intrinsically rapamycinsensitive were sensitive to MLN0128 in vitro. MLN0128 inhibite...

Szczegółowa specyfikacja

Zapisane w:
Opis bibliograficzny
Wydane w:Oncotarget
Główni autorzy: Hassan, Burhan, Akcakanat, Argun, Sangai, Takafumi, Evans, Kurt W., Adkins, Farrell, Eterovic, Agda Karina, Zhao, Hao, Chen, Ken, Chen, Huiqin, Do, Kim-Anh, Xie, Shelly M., Holder, Ashley M., Naing, Aung, Mills, Gordon B., Meric-Bernstam, Funda
Format: Artigo
Język:Inglês
Wydane: Impact Journals LLC 2014
Hasła przedmiotowe:
Research Paper
Dostęp online:https://ncbi.nlm.nih.gov/pmc/articles/PMC4226703/
https://ncbi.nlm.nih.gov/pubmed/25261369
Etykiety: Dodaj etykietę
Nie ma etykietki, Dołącz pierwszą etykiete!

Podobne zapisy